Skip to main content
DRMA
NASDAQ Life Sciences

Dermata Therapeutics Updates At-The-Market Offering Capacity to $705,000

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$3.02
Mkt Cap
$8.733M
52W Low
$1.58
52W High
$23.7
52W Position info
91% above low
Off High info
87% below high
Rel. Volume info
20× avg
Market data snapshot near publication time

DRMA sits 91% above its 52-week low of $1.58 on elevated volume (20× avg).

Summary

Dermata Therapeutics filed a prospectus supplement to update its At-The-Market (ATM) offering capacity, allowing it to sell up to an additional $705,000 in common stock.


Key Events · Financing and Capital Events · DRMA

  • Updates ATM Offering Capacity

    The company can now sell up to an additional $705,000 of common stock through its At-The-Market (ATM) offering.

  • Ongoing Dilution

    This update is part of an existing ATM program, which has already resulted in approximately $3.45 million in stock sales, indicating ongoing dilution for shareholders.

  • Capital for Operations

    For a micro-cap company, securing this capital is vital for funding operations and extending its financial runway, despite the dilutive effect.

  • Regulatory Constraints

    The offering is limited by SEC rules, specifically the one-third public float restriction for smaller reporting companies, indicating the company is near its maximum primary offering capacity.


Analysis · DRMA · Life Sciences

This filing updates Dermata Therapeutics' existing At-The-Market (ATM) offering, indicating the company can now sell up to an additional $705,000 worth of common stock. This capital raise, while dilutive, is crucial for a micro-cap company like Dermata Therapeutics to fund operations and extend its financial runway. The company has already sold approximately $3.45 million through this ATM program, and this update reflects the remaining capacity under SEC rules, specifically the one-third public float limitation for smaller reporting companies. This follows a recent S-3 registration for a separate resale offering by selling stockholders on January 22, 2026, and a significant personal investment by the CEO on January 8, 2026, which provided a positive signal amidst ongoing capital needs.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, DRMA was trading at $3.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.7M. The 52-week trading range was $1.58 to $23.70. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DRMA - Latest Insights

DRMA
Nov 10, 2026, 4:07 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.702
Real-time Price: $0.510 info
Change: -$0.192 (-27%) info
Market Cap: $2.512M info
DRMA
Nov 10, 2026, 4:05 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.720
Real-time Price: $0.510 info
Change: -$0.210 (-29%) info
Market Cap: $2.512M info
DRMA
Aug 17, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.43
Real-time Price: $0.510 info
Change: -$0.920 (-64%) info
Market Cap: $2.512M info
DRMA
Aug 11, 2026, 4:07 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1.71
Real-time Price: $0.510 info
Change: -$1.20 (-70%) info
Market Cap: $2.512M info
DRMA
Aug 11, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.10
Real-time Price: $0.510 info
Change: -$0.590 (-54%) info
Market Cap: $2.512M info